[WCN21;66;89]

New Therapies In Hereditary Amyloid Neuropathies

Teresa Coelho

Teresa Coelho is a Neurologist and Neurophysiologist at Hospital Santo António, Porto, Portugal, where clinical investigation led to Andrade’s description of transthyretin familial amyloid polyneuropathy (TTR-FAP), published in Brain in 1952.

The disease is nowadays named ATTR amyloidosis, emphasizing its systemic nature but neuropathy remains one of the most important aspects of the disease, along with cardiomyopathy.

Dr Coelho is the Head of Neurophysiology Department and the Head of Andrade’s Center for Familial Amyloidosis, an outpatient multidisciplinary clinic that is a Reference Centre for this condition. About a thousand patients are observed every year, including 50-60 newly diagnosed patients. Porto center participated actively in the clinical development of the three new drugs, Tafamidis, Patisiran and Inotersen, recently approved in Europe for the treatment of this condition and remains actively engaged in research and further development of new therapies.